ClinicalTrials.gg
CompletedNCT00236899Updated Sep 27, 2011Results posted

Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC

A Phase 3 interventional study of Gemcitabine and Docetaxel in Metastatic Breast Cancer (MBC), sponsored by Eli Lilly and Company. Completed at 34 sites in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-27.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
241
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Enrollment
56th of 248
241 · median 68
Started
2005
with 18 others
Phase 3
51 of 264
5 open now
Registered
97th of 264
by date

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 56th largest by enrollment of the 248 interventional ones that give a count, is one of 19 that started in 2005, is one of 51 in phase 3, and was the 97th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

Multi-center, randomized Phase III study. 4 arms. 360 Patient to enroll. Purpose is evaluate time to progression disease (PD).

03

Conditions studied

  • Metastatic Breast Cancer (MBC)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic diagnosis of breast cancer (MBC).
  • Prior or adjuvant taxanes regimen is allowed if ≥12 months since completion of the regimen.
  • Relapsing after receiving one adjuvant/neoadjuvant chemotherapy containing an anthracycline if not clinically .
  • Patients with .
  • Previous hormonal therapy for adjuvant setting or metastatic disease.

Exclusion criteria

Exclusion Criteria:

  • Previous chemotherapy for MBC
  • Previous chemotherapy with gemcitabine in any setting of disease
  • Patient candidable to treatment with trastuzumab.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
241 participants (actual)

Study arms

  • Experimental
    A: Docetaxel and Gemcitabine (Tri-weekly)

    Docetaxel and Gemcitabine (Tri-weekly)

    Drug: Gemcitabine · Drug: Docetaxel

  • Experimental
    B: Paclitaxel and Gemcitabine (Tri-weekly)

    Paclitaxel and Gemcitabine (Tri-weekly)

    Drug: Gemcitabine · Drug: Paclitaxel

  • Experimental
    C: Docetaxel and Gemcitabine (Weekly)

    Docetaxel and Gemcitabine (Weekly)

    Drug: Gemcitabine · Drug: Docetaxel

  • Experimental
    D: Paclitaxel and Gemcitabine (Weekly)

    Paclitaxel and Gemcitabine (Weekly)

    Drug: Gemcitabine · Drug: Paclitaxel

Interventions

  • Arm A: 1000 mg/m², 30 minute (min) intravenous (IV) infusion on Days 1 and 8, repeated every 21 days for 10 cycles for complete responders (CRs=disappearance of all target lesions) or partial responders (PRs≥30% decrease in sum of longest diameter of target lesions); 6 cycles for stable disease (SD=small changes that do not meet the above criteria); or until progressive disease (PD≥20% increase in sum of longest diameter of target lesions). Arm B: 1250 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. Arm C: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. Arm D: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.

    Also known as: LY188011, Gemzar

  • Arm A: 75 milligram per square meter (mg/m²), 60 min IV infusion on Day 1 only, to be given 30 min prior to Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. Arm C: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15, to be given 30 min prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.

  • Arm B: 175 mg/m², IV infusion over approximately 3 hours, followed by Gemcitabine, on Day 1, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. Arm D: 80 mg/m², IV infusion over approximately 1 hour, Days 1, 8, and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.

06

What researchers measure

Primary outcomes

  1. Time to Progressive Disease (TTPD) by Treatment Schedule

    TTPD is defined as the time from the day of treatment to first observation of documented disease progression or death due to any cause, whichever comes first. TTPD was censored at the time of last follow-up for patients who were still alive without progression. Tumor response was assessed in cancer patients by using Response Evaluation Criteria in Solid Tumors (RECIST), which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. Progressive Disease is a ≥20% increase in sum of longest diameter of target lesions.

    Time frame: Baseline up to 49.84 months

  2. Time to Progressive Disease (TTPD) by Treatment Drug

    TTPD is defined as the time from the day of treatment to first observation of documented disease progression or death due to any cause, whichever comes first. TTPD was censored at the time of last follow-up for patients who were still alive without progression. Tumor response was assessed in cancer patients by using Response Evaluation Criteria in Solid Tumors (RECIST), which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. Progressive Disease is a ≥20% increase in sum of longest diameter of target lesions.

    Time frame: Baseline up to 49.84 months

Secondary outcomes

  1. Overall Survival (OS) by Treatment Schedule

    OS is the duration from enrollment to time of death as a result of any cause. For participants who are alive, OS is censored at the last contact (date of the last follow-up visit).

    Time frame: Baseline up to 51.64 months

  2. Overall Survival (OS) by Treatment Drug

    OS is the duration from enrollment to time of death as a result of any cause. For participants who are alive, OS is censored at the last contact (date of the last follow-up visit).

    Time frame: Baseline up to 51.64 months

  3. Overall Response Rate (ORR) by Treatment Schedule

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response≥30% decrease in sum of longest diameter of target lesions; Progressive Disease≥20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Not Available=participants assessed whose data were not available. Not Assessed=participants who did not participate in assessments. The ORR=sum of complete and partial tumor responses observed, divided by the total number of evaluable participants.

    Time frame: Baseline up to 49.84 months

  4. Overall Response Rate(ORR) by Treatment Drug

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response≥30% decrease in sum of longest diameter of target lesions; Progressive Disease≥20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Not Available=participants assessed whose data were not available. Not Assessed=participants who did not participate in assessments. The ORR=sum of complete and partial tumor responses observed, divided by the total number of evaluable participants.

    Time frame: Baseline up to 49.84 months

  5. Number of Participants With Serious and Nonserious Adverse Events (AEs)

    Summary tables of serious adverse events (SAEs) and all other nonserious AEs are located in the Reported Adverse Event Module.

    Time frame: Baseline up to 51.64 months

  6. Quality of Life (QOL) Using the Rotterdam Symptom Scale Checklist (RSSC) at Beginning of 3-Week or 4-Week Cycle

    RSSC is a valid and reliable measure of psychological and physical distress of cancer patients. Overall QOL is assessed on a 7-point scale (1=Excellent to 7=Extremely Poor). Categories include Excellent, Good, Moderately Good, Neither Good nor Bad, Rather Poor, Poor, and Extremely Poor. Number of responses to the overall QOL by treatment arm are provided. Arms A (Docetaxel and Gemcitabine 3 Weekly) and B (Paclitaxel and Gemcitabine 3 Weekly) were assessed every 3 weeks. Arms C (Docetaxel and Gemcitabine Weekly) and D (Paclitaxel and Gemcitabine Weekly) were assessed every 4 weeks.

    Time frame: Baseline up to 51.64 months

  7. Quality of Life (QOL) Using the Rotterdam Symptom Scale Checklist (RSSC) at 30-Day Post-therapy Visit

    RSSC is a valid and reliable measure of psychological and physical distress of cancer patients. Overall QOL is assessed on a 7-point scale (1=Excellent to 7=Extremely Poor). Categories include Excellent, Good, Moderately Good, Neither Good nor Bad, Rather Poor, Poor, and Extremely Poor. Number of responses to the overall QOL (using the 7-point scale) by treatment arm are provided.

    Time frame: Baseline up to 51.64 months

07

Results

Posted Sep 27, 2011

Participant flow

Participant flow — Overall Study
MilestoneArm A: Docetaxel and Gemcitabine (Tri-weekly)Arm B: Paclitaxel and Gemcitabine (Tri-weekly)Arm C: Docetaxel and Gemcitabine (Weekly)Arm D: Paclitaxel and Gemcitabine (Weekly)
Started60645859
Completed18241419
Not completed42404440
Withdrew: Adverse event (study related)1121
Withdrew: Adverse event (not study related)3347
Withdrew: Death (study disease)1400
Withdrew: Death (not study related)2000
Withdrew: Death (study drug toxicity)1000
Withdrew: Lost to follow-up0100
Withdrew: Entry criteria exclusion0110
Withdrew: Protocol violation1000
Withdrew: Withdrawal by subject6452
Withdrew: Physician decision7876
Withdrew: Satisfactory response2001
Withdrew: Lack of efficacy18182523

Outcome measures

PrimaryTime to Progressive Disease (TTPD) by Treatment Schedule

TTPD is defined as the time from the day of treatment to first observation of documented disease progression or death due to any cause, whichever comes first. TTPD was censored at the time of last follow-up for patients who were still alive without progression. Tumor response was assessed in cancer patients by using Response Evaluation Criteria in Solid Tumors (RECIST), which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. Progressive Disease is a ≥20% increase in sum of longest diameter of target lesions.

Time frame:
Baseline up to 49.84 months
Reported as:
Median · months
Time to Progressive Disease (TTPD) by Treatment Schedule
monthsTreatment Schedule (Weekly)Treatment Schedule (3 Weekly)
Time to Progressive Disease (TTPD) by Treatment Schedule8.33 (6.19 to 10.16)7.51 (5.93 to 8.33)
Statistical analysis
  • Treatment Schedule (Weekly) vs Treatment Schedule (3 Weekly) · Regression, Cox · p = 0.345 · Hazard ratio (hr): 1.14 · 95% CI 0.87 to 1.50
SecondaryOverall Survival (OS) by Treatment Schedule

OS is the duration from enrollment to time of death as a result of any cause. For participants who are alive, OS is censored at the last contact (date of the last follow-up visit).

Time frame:
Baseline up to 51.64 months
Reported as:
Mean · months
Overall Survival (OS) by Treatment Schedule
monthsTreatment Schedule (Weekly)Treatment Schedule (3 Weekly)
Overall Survival (OS) by Treatment Schedule21.11 (17.28 to 26.75)20.95 (18.92 to 33.21)
Statistical analysis
  • Treatment Schedule (Weekly) vs Treatment Schedule (3 Weekly) · Regression, Cox · p = 0.885 · Hazard ratio (hr): 0.98 · 95% CI 0.69 to 1.37
SecondaryOverall Survival (OS) by Treatment Drug

OS is the duration from enrollment to time of death as a result of any cause. For participants who are alive, OS is censored at the last contact (date of the last follow-up visit).

Time frame:
Baseline up to 51.64 months
Reported as:
Median · months
Overall Survival (OS) by Treatment Drug
monthsTreatment Drug (Docetaxel)Treatment Drug (Paclitaxel)
Overall Survival (OS) by Treatment Drug19.11 (16.59 to 24.00)23.80 (19.38 to 31.97)
Statistical analysis
  • Treatment Drug (Docetaxel) vs Treatment Drug (Paclitaxel) · Regression, Cox · p = 0.976 · Hazard ratio (hr): 1.01 · 95% CI 0.71 to 1.42
SecondaryOverall Response Rate (ORR) by Treatment Schedule

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response≥30% decrease in sum of longest diameter of target lesions; Progressive Disease≥20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Not Available=participants assessed whose data were not available. Not Assessed=participants who did not participate in assessments. The ORR=sum of complete and partial tumor responses observed, divided by the total number of evaluable participants.

Time frame:
Baseline up to 49.84 months
Reported as:
Number · percentage of responses
Overall Response Rate (ORR) by Treatment Schedule
percentage of responsesTreatment Schedule (Weekly)Treatment Schedule (3 Weekly)
ORR (Complete Response or Partial Response)50.4333.06
Complete Response6.845.65
Partial Response43.5927.42
Stable Disease23.9340.32
Progressive Disease21.3712.90
Not Available0.851.61
Not Assessed3.4212.10
Statistical analysis
  • Treatment Schedule (Weekly) vs Treatment Schedule (3 Weekly) · Regression, Logistic · p = 0.0028 · Odds ratio (or): 0.442 · 95% CI 0.259 to 0.754
PrimaryTime to Progressive Disease (TTPD) by Treatment Drug

TTPD is defined as the time from the day of treatment to first observation of documented disease progression or death due to any cause, whichever comes first. TTPD was censored at the time of last follow-up for patients who were still alive without progression. Tumor response was assessed in cancer patients by using Response Evaluation Criteria in Solid Tumors (RECIST), which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. Progressive Disease is a ≥20% increase in sum of longest diameter of target lesions.

Time frame:
Baseline up to 49.84 months
Reported as:
Median · months
Time to Progressive Disease (TTPD) by Treatment Drug
monthsTreatment Drug (Docetaxel)Treatment Drug (Paclitaxel)
Time to Progressive Disease (TTPD) by Treatment Drug7.74 (5.57 to 9.80)7.80 (6.20 to 8.72)
Statistical analysis
  • Treatment Drug (Docetaxel) vs Treatment Drug (Paclitaxel) · Regression, Cox · p = 0.150 · Hazard ratio (hr): 1.23 · 95% CI 0.93 to 1.62
SecondaryOverall Response Rate(ORR) by Treatment Drug

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response≥30% decrease in sum of longest diameter of target lesions; Progressive Disease≥20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Not Available=participants assessed whose data were not available. Not Assessed=participants who did not participate in assessments. The ORR=sum of complete and partial tumor responses observed, divided by the total number of evaluable participants.

Time frame:
Baseline up to 49.84 months
Reported as:
Number · percentage of responses
Overall Response Rate(ORR) by Treatment Drug
percentage of responsesTreatment Drug (Docetaxel)Treatment Drug (Paclitaxel)
ORR (Complete Response or Partial Response)43.239.8
Complete Response5.087.32
Partial Response38.1432.52
Stable Disease32.2032.52
Progressive Disease17.8016.26
Not Available0.851.63
Not Assessed5.939.76
Statistical analysis
  • Treatment Drug (Docetaxel) vs Treatment Drug (Paclitaxel) · Regression, Logistic · p = 0.4567 · Odds ratio (or): 0.818 · 95% CI 0.482 to 1.389
SecondaryNumber of Participants With Serious and Nonserious Adverse Events (AEs)

Summary tables of serious adverse events (SAEs) and all other nonserious AEs are located in the Reported Adverse Event Module.

Time frame:
Baseline up to 51.64 months
Reported as:
Number · participants
Number of Participants With Serious and Nonserious Adverse Events (AEs)
participantsArm A: Docetaxel and Gemcitabine (Tri-weekly)Arm B: Paclitaxel and Gemcitabine (Tri-weekly)Arm C: Docetaxel and Gemcitabine (Weekly)Arm D: Paclitaxel and Gemcitabine (Weekly)
SAEs910711
Nonserious AEs57585356
SecondaryQuality of Life (QOL) Using the Rotterdam Symptom Scale Checklist (RSSC) at Beginning of 3-Week or 4-Week Cycle

RSSC is a valid and reliable measure of psychological and physical distress of cancer patients. Overall QOL is assessed on a 7-point scale (1=Excellent to 7=Extremely Poor). Categories include Excellent, Good, Moderately Good, Neither Good nor Bad, Rather Poor, Poor, and Extremely Poor. Number of responses to the overall QOL by treatment arm are provided. Arms A (Docetaxel and Gemcitabine 3 Weekly) and B (Paclitaxel and Gemcitabine 3 Weekly) were assessed every 3 weeks. Arms C (Docetaxel and Gemcitabine Weekly) and D (Paclitaxel and Gemcitabine Weekly) were assessed every 4 weeks.

Time frame:
Baseline up to 51.64 months
Reported as:
Number · participants
Quality of Life (QOL) Using the Rotterdam Symptom Scale Checklist (RSSC) at Beginning of 3-Week or 4-Week Cycle
participantsArm A: Docetaxel and Gemcitabine (Tri-weekly)Arm B: Paclitaxel and Gemcitabine (Tri-weekly)Arm C: Docetaxel and Gemcitabine (Weekly)Arm D: Paclitaxel and Gemcitabine (Weekly)
1=Excellent3124
2=Good131395
3=Moderately Good6899
4=Neither Good Nor Bad6767
5=Rather Poor2336
6=Poor0372
7=Extremely Poor0301
No Response30262225
Statistical analysis
  • Arm B: Paclitaxel and Gemcitabine (Tri-weekly) vs Arm D: Paclitaxel and Gemcitabine (Weekly) · Fisher Exact · p = 0.142 (This is the p-value for Treatment Schedule (Docetaxel and Gemcitabine 3 Weekly + Paclitaxel and Gemcitabine 3 Weekly) and Treatment Drug (Docetaxel and Gemcitabine Weekly + Paclitaxel and Gemcitabine Weekly).)
  • Arm A: Docetaxel and Gemcitabine (Tri-weekly) vs Arm C: Docetaxel and Gemcitabine (Weekly) · Fisher Exact · p = 0.470 (This is the p-value for Treatment Drug (Docetaxel and Gemcitabine 3 Weekly + Docetaxel and Gemcitabine Weekly vs Paclitaxel and Gemcitabine 3 Weekly + Paclitaxel and Gemcitabine Weekly).)
SecondaryQuality of Life (QOL) Using the Rotterdam Symptom Scale Checklist (RSSC) at 30-Day Post-therapy Visit

RSSC is a valid and reliable measure of psychological and physical distress of cancer patients. Overall QOL is assessed on a 7-point scale (1=Excellent to 7=Extremely Poor). Categories include Excellent, Good, Moderately Good, Neither Good nor Bad, Rather Poor, Poor, and Extremely Poor. Number of responses to the overall QOL (using the 7-point scale) by treatment arm are provided.

Time frame:
Baseline up to 51.64 months
Reported as:
Number · participants
Quality of Life (QOL) Using the Rotterdam Symptom Scale Checklist (RSSC) at 30-Day Post-therapy Visit
participantsArm A: Docetaxel and Gemcitabine (Tri-weekly)Arm B: Paclitaxel and Gemcitabine (Tri-weekly)Arm C: Docetaxel and Gemcitabine (Weekly)Arm D: Paclitaxel and Gemcitabine (Weekly)
1=Excellent0000
2=Good7724
3=Moderately Good2632
4=Neither Good Nor Bad3603
5=Rather Poor0111
6=Poor2012
7=Extremely Poor1020
No Response45444947
Statistical analysis
  • Arm B: Paclitaxel and Gemcitabine (Tri-weekly) vs Arm D: Paclitaxel and Gemcitabine (Weekly) · Fisher Exact · p = 0.293 (This is the p-value for Treatment Schedule (Docetaxel and Gemcitabine 3 Weekly + Paclitaxel and Gemcitabine 3 Weekly) and Treatment Drug (Docetaxel and Gemcitabine Weekly + Paclitaxel and Gemcitabine Weekly).)
  • Arm A: Docetaxel and Gemcitabine (Tri-weekly) vs Arm C: Docetaxel and Gemcitabine (Weekly) · Fisher Exact · p = 0.476 (This is the p-value for Treatment Drug (Docetaxel and Gemcitabine 3 Weekly + Docetaxel and Gemcitabine Weekly vs Paclitaxel and Gemcitabine 3 Weekly + Paclitaxel and Gemcitabine Weekly).)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Docetaxel and Gemcitabine (Tri-weekly)—9/59 (15.3%)57/59 (96.6%)
Arm B: Paclitaxel and Gemcitabine (Tri-weekly)—10/62 (16.1%)58/62 (93.5%)
Arm C: Docetaxel and Gemcitabine (Weekly)—7/58 (12.1%)53/58 (91.4%)
Arm D: Paclitaxel and Gemcitabine (Weekly)—11/59 (18.6%)56/59 (94.9%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventArm A: Docetaxel and Gemcitabine (Tri-weekly)Arm B: Paclitaxel and Gemcitabine (Tri-weekly)Arm C: Docetaxel and Gemcitabine (Weekly)Arm D: Paclitaxel and Gemcitabine (Weekly)
NeutropeniaBlood and lymphatic system disorders4/591/620/581/59
AnaemiaBlood and lymphatic system disorders0/591/620/582/59
DiarrhoeaGastrointestinal disorders2/590/621/580/59
AstheniaGeneral disorders0/590/621/582/59
DyspnoeaRespiratory, thoracic and mediastinal disorders2/590/620/580/59
Oedema peripheralGeneral disorders0/590/621/580/59
BronchitisInfections and infestations0/590/621/580/59
Device related infectionInfections and infestations0/590/621/580/59
Meningitis pneumococcalInfections and infestations0/590/621/580/59
OsteonecrosisMusculoskeletal and connective tissue disorders0/590/621/580/59
Most frequent other events
Showing 10 of 55
Most frequent other events
EventArm A: Docetaxel and Gemcitabine (Tri-weekly)Arm B: Paclitaxel and Gemcitabine (Tri-weekly)Arm C: Docetaxel and Gemcitabine (Weekly)Arm D: Paclitaxel and Gemcitabine (Weekly)
NeutropeniaBlood and lymphatic system disorders50/5933/6220/5838/59
NauseaGastrointestinal disorders25/5921/6220/5821/59
PyrexiaGeneral disorders17/5916/6223/5817/59
AlopeciaSkin and subcutaneous tissue disorders22/5918/6214/5816/59
DiarrhoeaGastrointestinal disorders18/5911/6221/5814/59
LeukopeniaBlood and lymphatic system disorders21/599/6214/5813/59
Alanine aminotransferase increasedInvestigations11/5914/6217/5820/59
AstheniaGeneral disorders17/5918/6218/5815/59
FatigueGeneral disorders15/5912/6213/5818/59
AnaemiaBlood and lymphatic system disorders12/5910/6212/5817/59

Baseline characteristics

Age Continuous
Age Continuous(years)Arm A: Docetaxel and Gemcitabine (Tri-weekly)Arm B: Paclitaxel and Gemcitabine (Tri-weekly)Arm C: Docetaxel and Gemcitabine (Weekly)Arm D: Paclitaxel and Gemcitabine (Weekly)Total
Mean56.58 ± 10.2156.31 ± 9.8455.78 ± 8.9954.66 ± 10.0455.85 ± 9.76
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Docetaxel and Gemcitabine (Tri-weekly)Arm B: Paclitaxel and Gemcitabine (Tri-weekly)Arm C: Docetaxel and Gemcitabine (Weekly)Arm D: Paclitaxel and Gemcitabine (Weekly)Total
Female60645859241
Male00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Arm A: Docetaxel and Gemcitabine (Tri-weekly)Arm B: Paclitaxel and Gemcitabine (Tri-weekly)Arm C: Docetaxel and Gemcitabine (Weekly)Arm D: Paclitaxel and Gemcitabine (Weekly)Total
Caucasian58635859238
Other21003
Region of Enrollment
Region of Enrollment(participants)Arm A: Docetaxel and Gemcitabine (Tri-weekly)Arm B: Paclitaxel and Gemcitabine (Tri-weekly)Arm C: Docetaxel and Gemcitabine (Weekly)Arm D: Paclitaxel and Gemcitabine (Weekly)Total
Italy60645859241
Menopausal Status
Menopausal Status(participants)Arm A: Docetaxel and Gemcitabine (Tri-weekly)Arm B: Paclitaxel and Gemcitabine (Tri-weekly)Arm C: Docetaxel and Gemcitabine (Weekly)Arm D: Paclitaxel and Gemcitabine (Weekly)Total
Premenopausal1917162173
Postmenopausal41474238168
Previous Hormonal Therapy
Previous Hormonal Therapy(participants)Arm A: Docetaxel and Gemcitabine (Tri-weekly)Arm B: Paclitaxel and Gemcitabine (Tri-weekly)Arm C: Docetaxel and Gemcitabine (Weekly)Arm D: Paclitaxel and Gemcitabine (Weekly)Total
Yes44484046178
No1616171362
Unknown00101
Presence or Absence of Visceral Metastases
Presence or Absence of Visceral Metastases(participants)Arm A: Docetaxel and Gemcitabine (Tri-weekly)Arm B: Paclitaxel and Gemcitabine (Tri-weekly)Arm C: Docetaxel and Gemcitabine (Weekly)Arm D: Paclitaxel and Gemcitabine (Weekly)Total
Absence1919162377
Presence41454236164
Number of Participants with Previous Adjuvant/Neoadjuvant Taxane Therapy
Number of Participants with Previous Adjuvant/Neoadjuvant Taxane Therapy(participants)Arm A: Docetaxel and Gemcitabine (Tri-weekly)Arm B: Paclitaxel and Gemcitabine (Tri-weekly)Arm C: Docetaxel and Gemcitabine (Weekly)Arm D: Paclitaxel and Gemcitabine (Weekly)Total
Yes2124121976
No39404540164
Unknown00101

1 further baseline measures are reported on the registry.

08

Study locations

34 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Avellino, 50019, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bologna, 40100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brescia, 25124, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cagliari, 09042, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Candiolo-Torino, 10060, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Casale Monferrato, 15033, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Castelfranco Veneto, 31033, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Catania, 95126, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cuneo, 12100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ferrara, 44100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frosinone, 03100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Genova, 16132, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gorgonzola, 20064, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lecce, 73100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mantova, 46100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milano, 20162, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Napoli, 80131, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Negrar, 37024, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Padova, 35128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Parma, 43100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Piacenza, 29100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pisa, 56100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Potenza, 85028, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Reggio Calabria, 89100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rome, 00161, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Sisto, 06156, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sassari, 07100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taormina, 98039, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Torino, 10126, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Trento, 38100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Treviglio, 24047, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Trieste, 34142, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Udine, 33100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Viterbo, 01100, Italy
09

References and documents

Publications

  • Del Mastro L, Fabi A, Mansutti M, De Laurentiis M, Durando A, Merlo DF, Bruzzi P, La Torre I, Ceccarelli M, Kazeem G, Marchi P, Boy D, Venturini M, De Placido S, Cognetti F. Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. BMC Cancer. 2013 Mar 28;13:164. doi: 10.1186/1471-2407-13-164. PubMed 23537313 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2005
First posted
Oct 12, 2005
Start
Sep 2005
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Results first posted
Sep 27, 2011
Last update
Sep 27, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00236899
Responsible party
Sponsor
First posted
Oct 12, 2005
Start date
Sep 2005
Primary completion
Aug 2010
Completion
Aug 2010
Results posted
Sep 27, 2011
Last update
Sep 27, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)
study chair · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Paclitaxel

Start the discussion